BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib <i>in vitro</i> and <i>in vivo</i> by promoting mitochondrial pathway-mediated cell apoptosis

Abstract

Combination of bortezomib with nitroxoline has a synergistic anti-tumor activity in MM cells and may be a novel treatment method for MM.